| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsMay 6, 2025 |
|
These studies reveal a drug’s active free fraction, which impacts safety and efficacy. QPS experts explain the methods to determine plasma protein binding. Download the QPS white paper: Plasma Protein Binding 
|
|
| By Eric Sagonowsky In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics Evaluation and Research. |
|
|
|
By Gabrielle Masson Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis trial over a tolerability issue, while reporting a separate impairment charge of $379 million tied to an earlier discontinuation. |
By Fraiser Kansteiner Bristol Myers Squibb plans to invest $40 billion across U.S. R&D, technology and manufacturing over the next five years, CEO Chris Boerner said in an op-ed published by Stat this week. |
By Conor Hale Abbott’s test for mild traumatic brain injuries is making its sporting debut through the motorcycle racing series MotoAmerica, marking the first professional organization to deploy the screener at its competitions. |
|
Thursday, May 15, 2025 | 12pm ET / 9am PT Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain. 
|
|
By Gabrielle Masson The National Institutes of Health has laid off 250 more employees, with this round of cuts also hitting 50 workers at the National Cancer Institute. |
By Ben Adams Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. |
By Angus Liu In President Donald Trump’s latest push to bring pharmaceutical manufacturing to the U.S., a new executive order tasks the FDA with reducing regulatory hurdles for domestic producers while making life harder for foreign manufacturers. |
By Andrea Park The “ConnectING with Carnie” campaign page, hosted within the official Ingrezza website, includes testimonials from people with TD about the ways their lives changed after speaking up about their symptoms. |
By Conor Hale The FDA elevated a recall of intraocular lenses currently being wrapped up by Bausch + Lomb, following increased reports of inflammatory reactions from patients who underwent cataract surgery. |
By Zoey Becker Novartis initially sued Incyte in 2020, claiming that the Jakafi maker skimped out on paying owed royalties from their 2009 license agreement. |
By Darren Incorvaia Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round. |
By Nick Paul Taylor Havas Life has put down roots in the Middle East. The agency’s newest office will provide healthcare advertising and strategic communications across the Middle East and North Africa region. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," hear how the founders of ElevAAte are turning shared East Asian American experiences into collective power for the next generation of biopharma leaders. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| |
|
